Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
The efficacy and safety of combining bevacizumab (7.5 and 15 mg/kg) with docetaxel as first-line therapy for human epidermal growth factor receptor 2 (HER2) -negative, locally recurrent or metastatic breast cancer (MBC) was investigated in a three-arm, placebo-controlled, phase III trial. Patients (...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical oncology Jg. 28; H. 20; S. 3239 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
10.07.2010
|
| Schlagworte: | |
| ISSN: | 1527-7755, 1527-7755 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | The efficacy and safety of combining bevacizumab (7.5 and 15 mg/kg) with docetaxel as first-line therapy for human epidermal growth factor receptor 2 (HER2) -negative, locally recurrent or metastatic breast cancer (MBC) was investigated in a three-arm, placebo-controlled, phase III trial.
Patients (N = 736) were randomly assigned to docetaxel 100 mg/m(2) plus either placebo or bevacizumab 7.5 or 15 mg/kg every 3 weeks. The primary end point was progression-free survival (PFS); secondary end points included best overall response, duration of response, time to treatment failure, overall survival, and safety.
Combination of bevacizumab 15 mg/kg, but not 7.5 mg/kg, with docetaxel showed superior median PFS (mPFS) to placebo plus docetaxel in unstratified analysis (placebo mPFS, 8.2 months; 7.5 mg/kg mPFS, 9.0 months [hazard ratio (HR), 0.86; P = .12]; 15 mg/kg mPFS, 10.1 months [HR, 0.77; P = .006]) and stratified analysis (placebo mPFS, 8.1 months; 7.5 mg/kg mPFS, 9.0 months [HR, 0.80; P = .045]; 15 mg/kg mPFS, 10.0 months [HR, 0.67; P < .001]). Response rates in patients with measurable disease at baseline also increased with bevacizumab 15 mg/kg (46% [placebo] v 55% [7.5 mg/kg; P = .07] and 64% [15 mg/kg; P < .001]). Combination with bevacizumab had limited impact on the known toxicity profile of docetaxel.
Combination of bevacizumab with docetaxel did not significantly impact on the safety profile of docetaxel. Bevacizumab 15 mg/kg every 3 weeks significantly increased PFS when combined with docetaxel as first-line therapy for MBC compared with docetaxel plus placebo. |
|---|---|
| AbstractList | The efficacy and safety of combining bevacizumab (7.5 and 15 mg/kg) with docetaxel as first-line therapy for human epidermal growth factor receptor 2 (HER2) -negative, locally recurrent or metastatic breast cancer (MBC) was investigated in a three-arm, placebo-controlled, phase III trial.
Patients (N = 736) were randomly assigned to docetaxel 100 mg/m(2) plus either placebo or bevacizumab 7.5 or 15 mg/kg every 3 weeks. The primary end point was progression-free survival (PFS); secondary end points included best overall response, duration of response, time to treatment failure, overall survival, and safety.
Combination of bevacizumab 15 mg/kg, but not 7.5 mg/kg, with docetaxel showed superior median PFS (mPFS) to placebo plus docetaxel in unstratified analysis (placebo mPFS, 8.2 months; 7.5 mg/kg mPFS, 9.0 months [hazard ratio (HR), 0.86; P = .12]; 15 mg/kg mPFS, 10.1 months [HR, 0.77; P = .006]) and stratified analysis (placebo mPFS, 8.1 months; 7.5 mg/kg mPFS, 9.0 months [HR, 0.80; P = .045]; 15 mg/kg mPFS, 10.0 months [HR, 0.67; P < .001]). Response rates in patients with measurable disease at baseline also increased with bevacizumab 15 mg/kg (46% [placebo] v 55% [7.5 mg/kg; P = .07] and 64% [15 mg/kg; P < .001]). Combination with bevacizumab had limited impact on the known toxicity profile of docetaxel.
Combination of bevacizumab with docetaxel did not significantly impact on the safety profile of docetaxel. Bevacizumab 15 mg/kg every 3 weeks significantly increased PFS when combined with docetaxel as first-line therapy for MBC compared with docetaxel plus placebo. The efficacy and safety of combining bevacizumab (7.5 and 15 mg/kg) with docetaxel as first-line therapy for human epidermal growth factor receptor 2 (HER2) -negative, locally recurrent or metastatic breast cancer (MBC) was investigated in a three-arm, placebo-controlled, phase III trial.PURPOSEThe efficacy and safety of combining bevacizumab (7.5 and 15 mg/kg) with docetaxel as first-line therapy for human epidermal growth factor receptor 2 (HER2) -negative, locally recurrent or metastatic breast cancer (MBC) was investigated in a three-arm, placebo-controlled, phase III trial.Patients (N = 736) were randomly assigned to docetaxel 100 mg/m(2) plus either placebo or bevacizumab 7.5 or 15 mg/kg every 3 weeks. The primary end point was progression-free survival (PFS); secondary end points included best overall response, duration of response, time to treatment failure, overall survival, and safety.PATIENTS AND METHODSPatients (N = 736) were randomly assigned to docetaxel 100 mg/m(2) plus either placebo or bevacizumab 7.5 or 15 mg/kg every 3 weeks. The primary end point was progression-free survival (PFS); secondary end points included best overall response, duration of response, time to treatment failure, overall survival, and safety.Combination of bevacizumab 15 mg/kg, but not 7.5 mg/kg, with docetaxel showed superior median PFS (mPFS) to placebo plus docetaxel in unstratified analysis (placebo mPFS, 8.2 months; 7.5 mg/kg mPFS, 9.0 months [hazard ratio (HR), 0.86; P = .12]; 15 mg/kg mPFS, 10.1 months [HR, 0.77; P = .006]) and stratified analysis (placebo mPFS, 8.1 months; 7.5 mg/kg mPFS, 9.0 months [HR, 0.80; P = .045]; 15 mg/kg mPFS, 10.0 months [HR, 0.67; P < .001]). Response rates in patients with measurable disease at baseline also increased with bevacizumab 15 mg/kg (46% [placebo] v 55% [7.5 mg/kg; P = .07] and 64% [15 mg/kg; P < .001]). Combination with bevacizumab had limited impact on the known toxicity profile of docetaxel.RESULTSCombination of bevacizumab 15 mg/kg, but not 7.5 mg/kg, with docetaxel showed superior median PFS (mPFS) to placebo plus docetaxel in unstratified analysis (placebo mPFS, 8.2 months; 7.5 mg/kg mPFS, 9.0 months [hazard ratio (HR), 0.86; P = .12]; 15 mg/kg mPFS, 10.1 months [HR, 0.77; P = .006]) and stratified analysis (placebo mPFS, 8.1 months; 7.5 mg/kg mPFS, 9.0 months [HR, 0.80; P = .045]; 15 mg/kg mPFS, 10.0 months [HR, 0.67; P < .001]). Response rates in patients with measurable disease at baseline also increased with bevacizumab 15 mg/kg (46% [placebo] v 55% [7.5 mg/kg; P = .07] and 64% [15 mg/kg; P < .001]). Combination with bevacizumab had limited impact on the known toxicity profile of docetaxel.Combination of bevacizumab with docetaxel did not significantly impact on the safety profile of docetaxel. Bevacizumab 15 mg/kg every 3 weeks significantly increased PFS when combined with docetaxel as first-line therapy for MBC compared with docetaxel plus placebo.CONCLUSIONCombination of bevacizumab with docetaxel did not significantly impact on the safety profile of docetaxel. Bevacizumab 15 mg/kg every 3 weeks significantly increased PFS when combined with docetaxel as first-line therapy for MBC compared with docetaxel plus placebo. |
| Author | Dirix, Luc Y Romieu, Gilles Chan, Arlene Schneeweiss, Andreas Tomczak, Piotr Delozier, Thierry Harbeck, Nadia Steger, Guenther G Puglisi, Fabio Pivot, Xavier Provencher, Louise Miles, David W Sohn, Joo Hyuk Wardley, Andrew M Chlistalla, Andreas Cortés, Javier |
| Author_xml | – sequence: 1 givenname: David W surname: Miles fullname: Miles, David W email: david.miles@doctors.org.uk organization: Mount Vernon Cancer Centre, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom. david.miles@doctors.org.uk – sequence: 2 givenname: Arlene surname: Chan fullname: Chan, Arlene – sequence: 3 givenname: Luc Y surname: Dirix fullname: Dirix, Luc Y – sequence: 4 givenname: Javier surname: Cortés fullname: Cortés, Javier – sequence: 5 givenname: Xavier surname: Pivot fullname: Pivot, Xavier – sequence: 6 givenname: Piotr surname: Tomczak fullname: Tomczak, Piotr – sequence: 7 givenname: Thierry surname: Delozier fullname: Delozier, Thierry – sequence: 8 givenname: Joo Hyuk surname: Sohn fullname: Sohn, Joo Hyuk – sequence: 9 givenname: Louise surname: Provencher fullname: Provencher, Louise – sequence: 10 givenname: Fabio surname: Puglisi fullname: Puglisi, Fabio – sequence: 11 givenname: Nadia surname: Harbeck fullname: Harbeck, Nadia – sequence: 12 givenname: Guenther G surname: Steger fullname: Steger, Guenther G – sequence: 13 givenname: Andreas surname: Schneeweiss fullname: Schneeweiss, Andreas – sequence: 14 givenname: Andrew M surname: Wardley fullname: Wardley, Andrew M – sequence: 15 givenname: Andreas surname: Chlistalla fullname: Chlistalla, Andreas – sequence: 16 givenname: Gilles surname: Romieu fullname: Romieu, Gilles |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20498403$$D View this record in MEDLINE/PubMed |
| BookMark | eNpdkD1P5DAURS3EigGWngq5o8qs7dhxpkQjWAYhQbFbj17s55mgJA62w8f-N_4bHgHSiupe6Z13intE9gc_ICGnnM25YOzXzfJunrOeCz6vpNJ75JAroQutldr_r8_IUYwPjHFZl-qAzASTi1qy8pC83W8hIl2tVjSmyb5S72iDT2Daf1MPDR27KVLrDSZ4wY4a348Q0NLnNm3zEQw2_jvkfKBpi9S1IaaiawekKSCkHoe082-zeaA4thZDDx3dBP-cbQ5Myp8BDY67IooBN5DaJ6R9NseUu6FNNsVEDQwGw0_yw0EX8eQzj8nfq8s_y-vi9u73anlxW5hyoVMhlLRS532YddYpBM2VZdZWjSkrY2UNli8cL8FUppHAbaPUQlvnBLCaCymOyfmHdwz-ccKY1n0bDXYdDOinuNZlWSmp6x159klOTY92PYa2h_C6_lpcvAMvBIoj |
| CitedBy_id | crossref_primary_10_1007_s00280_013_2125_x crossref_primary_10_1007_s40487_025_00379_7 crossref_primary_10_1002_1878_0261_12561 crossref_primary_10_3390_cancers11091334 crossref_primary_10_1016_j_ejca_2011_11_021 crossref_primary_10_1038_s41416_024_02602_0 crossref_primary_10_1159_000350497 crossref_primary_10_1200_JCO_2010_32_0275 crossref_primary_10_1002_psp4_12693 crossref_primary_10_1093_jnci_djt114 crossref_primary_10_1517_14712598_2012_758705 crossref_primary_10_1016_j_clbc_2012_05_001 crossref_primary_10_1016_j_breast_2013_09_009 crossref_primary_10_3892_mco_2015_720 crossref_primary_10_1016_S1470_2045_15_00470_2 crossref_primary_10_1038_bjc_2015_419 crossref_primary_10_1002_14651858_CD008941_pub2 crossref_primary_10_1188_13_CJON_S1_22_34 crossref_primary_10_3390_cancers14153729 crossref_primary_10_1016_j_ajpath_2013_07_005 crossref_primary_10_1007_s12032_015_0533_y crossref_primary_10_1007_s00280_013_2233_7 crossref_primary_10_3389_fphar_2022_838133 crossref_primary_10_1016_j_breast_2014_11_003 crossref_primary_10_1093_annonc_mdw572 crossref_primary_10_1038_s41591_025_03734_3 crossref_primary_10_1172_JCI57152 crossref_primary_10_1155_2014_919570 crossref_primary_10_3390_jcm9061663 crossref_primary_10_1371_journal_pone_0187063 crossref_primary_10_1016_j_ejphar_2013_03_035 crossref_primary_10_1200_JCO_2010_31_9129 crossref_primary_10_3390_ph18020262 crossref_primary_10_1007_s00280_013_2100_6 crossref_primary_10_1016_j_molonc_2012_03_006 crossref_primary_10_1016_S1359_6349_11_70008_8 crossref_primary_10_1055_s_0043_57247 crossref_primary_10_1093_annonc_mdw316 crossref_primary_10_1016_j_ctrv_2016_12_009 crossref_primary_10_1007_s00280_013_2124_y crossref_primary_10_1016_j_jnci_2016_03_001 crossref_primary_10_1016_S1470_2045_12_70275_9 crossref_primary_10_1002_cam4_447 crossref_primary_10_1016_j_breast_2020_09_011 crossref_primary_10_5306_wjco_v5_i2_125 crossref_primary_10_3389_fimmu_2019_01984 crossref_primary_10_1177_2042098611430109 crossref_primary_10_1200_JCO_2015_66_1595 crossref_primary_10_1371_journal_pone_0089960 crossref_primary_10_5694_mja11_10599 crossref_primary_10_1002_sim_5487 crossref_primary_10_12771_emj_2014_37_2_75 crossref_primary_10_1007_s00520_014_2465_z crossref_primary_10_1259_bjrcr_20140065 crossref_primary_10_1002_ijc_29656 crossref_primary_10_1093_annonc_mdt276 crossref_primary_10_1158_1078_0432_CCR_12_1611 crossref_primary_10_1007_s10549_011_1776_8 crossref_primary_10_1002_phar_1506 crossref_primary_10_1093_annonc_mdw665 crossref_primary_10_1016_j_clbc_2011_04_001 crossref_primary_10_1158_1078_0432_CCR_14_3135 crossref_primary_10_1371_journal_pone_0086583 crossref_primary_10_3390_pharmaceutics4030442 crossref_primary_10_1016_j_ctrv_2016_12_002 crossref_primary_10_1200_JCO_2011_36_7771 crossref_primary_10_1016_j_mehy_2020_110399 crossref_primary_10_1158_1078_0432_CCR_11_1918 crossref_primary_10_1016_S1470_2045_14_70444_9 crossref_primary_10_1093_annonc_mds194 crossref_primary_10_1007_s00228_015_1818_y crossref_primary_10_2217_WHE_11_5 crossref_primary_10_1038_nrc3125 crossref_primary_10_1080_14728214_2021_1916468 crossref_primary_10_2165_11590180_000000000_00000 crossref_primary_10_1016_j_jtbi_2018_11_018 crossref_primary_10_1007_s40265_014_0302_9 crossref_primary_10_1111_tbj_13713 crossref_primary_10_1007_s10269_011_1996_x crossref_primary_10_1089_jpm_2012_0050 crossref_primary_10_1093_annonc_mdw260 crossref_primary_10_3892_mmr_2015_3405 crossref_primary_10_1158_1078_0432_CCR_10_1277 crossref_primary_10_1038_s41598_021_81914_0 crossref_primary_10_4137_BCBCR_S6562 crossref_primary_10_1007_s10456_019_09697_7 crossref_primary_10_1517_14712598_2015_963052 crossref_primary_10_1186_s40169_018_0185_6 crossref_primary_10_1200_JCO_2018_79_2028 crossref_primary_10_1016_j_clbc_2011_03_019 crossref_primary_10_1200_JCO_2012_41_9580 crossref_primary_10_3389_fonc_2023_1076469 crossref_primary_10_1016_j_clbc_2012_04_002 crossref_primary_10_3390_jcm9010084 crossref_primary_10_1038_bjc_2013_69 crossref_primary_10_1186_bcr3685 crossref_primary_10_1186_s40545_015_0046_2 crossref_primary_10_1016_j_critrevonc_2019_102855 crossref_primary_10_1016_j_ctrv_2011_08_001 crossref_primary_10_1007_s10549_011_1875_6 crossref_primary_10_1007_s13277_014_2799_7 crossref_primary_10_1007_s40265_013_0091_6 crossref_primary_10_1186_s12957_021_02441_w crossref_primary_10_1200_JCO_2010_32_9060 crossref_primary_10_1517_14740338_2011_594038 crossref_primary_10_1002_ijc_31645 crossref_primary_10_1088_0031_9155_60_4_1477 crossref_primary_10_1517_14656566_2012_652088 crossref_primary_10_1007_s12282_022_01399_1 crossref_primary_10_1007_s12609_011_0068_y crossref_primary_10_1517_14656566_2015_1032246 crossref_primary_10_1016_j_clbc_2014_10_006 crossref_primary_10_2146_ajhp110697 crossref_primary_10_1371_journal_pcbi_1005724 crossref_primary_10_1111_1759_7714_12627 crossref_primary_10_3109_0284186X_2011_631579 crossref_primary_10_3348_kjr_2020_0760 crossref_primary_10_1002_pbc_25036 crossref_primary_10_1016_j_ctrv_2012_05_004 crossref_primary_10_1016_j_ejca_2011_03_005 crossref_primary_10_1016_j_critrevonc_2017_11_005 crossref_primary_10_1016_j_ejca_2014_10_008 crossref_primary_10_3390_cancers12082122 crossref_primary_10_1177_107327481201900407 crossref_primary_10_1161_JAHA_117_006278 crossref_primary_10_1016_j_ijpharm_2017_11_011 crossref_primary_10_1016_j_lungcan_2013_05_021 crossref_primary_10_1016_j_clbc_2011_03_005 crossref_primary_10_1107_S1600577517008372 crossref_primary_10_3390_cancers13051080 crossref_primary_10_1007_s00520_011_1308_4 crossref_primary_10_1016_j_breast_2016_06_024 crossref_primary_10_1186_s43141_021_00174_7 crossref_primary_10_1016_j_breast_2011_06_004 crossref_primary_10_1016_j_clbc_2014_07_007 crossref_primary_10_1093_annonc_mdr043 crossref_primary_10_12968_bjon_2012_21_Sup4_S18 crossref_primary_10_2217_fon_13_197 crossref_primary_10_1517_14712598_2012_704015 crossref_primary_10_1080_14656566_2017_1309024 crossref_primary_10_1002_onco_13971 crossref_primary_10_1371_journal_pone_0234520 crossref_primary_10_2165_11595910_000000000_00000 crossref_primary_10_1007_s12032_014_0276_1 crossref_primary_10_1016_j_clon_2011_03_013 crossref_primary_10_1038_s41568_024_00736_0 crossref_primary_10_3390_ijms24119343 crossref_primary_10_1155_2011_284584 crossref_primary_10_1073_pnas_1203275109 crossref_primary_10_1093_annonc_mdt213 crossref_primary_10_1007_s10456_014_9420_y crossref_primary_10_1016_j_critrevonc_2011_03_002 crossref_primary_10_1016_j_critrevonc_2011_03_003 crossref_primary_10_1016_j_jpainsymman_2016_09_011 crossref_primary_10_1038_bjc_2014_430 crossref_primary_10_1634_theoncologist_2012_0115 crossref_primary_10_1038_srep15746 crossref_primary_10_3892_ol_2018_9057 crossref_primary_10_1016_j_ejca_2017_01_026 crossref_primary_10_1016_j_ejca_2017_01_027 crossref_primary_10_1016_j_clbc_2012_03_005 crossref_primary_10_1016_j_biopha_2013_03_006 crossref_primary_10_1016_j_ces_2023_118965 crossref_primary_10_1016_S1470_2045_15_00124_2 crossref_primary_10_1038_nrclinonc_2010_217 crossref_primary_10_1038_bcj_2012_12 crossref_primary_10_2165_11594480_000000000_00000 crossref_primary_10_4251_wjgo_v16_i5_2091 crossref_primary_10_1093_annonc_mds237 crossref_primary_10_1007_s10549_011_1685_x crossref_primary_10_1093_annonc_mdt323 crossref_primary_10_3390_jpm10030079 crossref_primary_10_1080_14712598_2017_1289171 crossref_primary_10_3389_fcell_2017_00101 crossref_primary_10_1016_S1470_2045_10_70259_X crossref_primary_10_1186_s12885_020_6674_1 crossref_primary_10_1517_14728222_2013_757305 crossref_primary_10_1158_0008_5472_CAN_11_2167 crossref_primary_10_1007_s10549_015_3453_9 crossref_primary_10_1634_theoncologist_2012_0024 crossref_primary_10_1016_S1470_2045_11_70037_7 crossref_primary_10_3892_ijo_2016_3553 crossref_primary_10_1016_j_biopha_2018_10_183 crossref_primary_10_1038_nrclinonc_2010_122 crossref_primary_10_3390_ijms14059338 crossref_primary_10_1200_JCO_2012_43_6931 crossref_primary_10_3892_etm_2014_1603 crossref_primary_10_1080_13543784_2017_1386172 crossref_primary_10_1016_j_ctrv_2014_05_006 crossref_primary_10_1371_journal_pone_0035629 crossref_primary_10_1007_s12032_012_0434_2 crossref_primary_10_1007_s10147_020_01826_3 crossref_primary_10_1016_j_ctrv_2020_102017 crossref_primary_10_1038_bjc_2013_725 crossref_primary_10_1093_annonc_mdv619 crossref_primary_10_1186_s12967_018_1514_7 crossref_primary_10_1016_j_critrevonc_2024_104546 crossref_primary_10_1200_JCO_2012_46_3653 crossref_primary_10_2147_IJN_S274083 crossref_primary_10_1186_1471_2407_12_620 crossref_primary_10_1177_1078155213510193 crossref_primary_10_1016_j_critrevonc_2012_02_010 crossref_primary_10_1186_bcr3064 crossref_primary_10_3389_fonc_2014_00346 crossref_primary_10_1038_nrclinonc_2011_151 crossref_primary_10_1371_journal_pone_0033576 crossref_primary_10_1093_annonc_mds590 crossref_primary_10_1200_JCO_2013_48_6894 crossref_primary_10_1016_j_addr_2013_09_001 crossref_primary_10_1007_s11523_014_0334_9 crossref_primary_10_1038_s41523_022_00400_6 crossref_primary_10_1016_j_patbio_2012_05_012 crossref_primary_10_1038_nrclinonc_2010_154 crossref_primary_10_1016_j_ejca_2025_115689 crossref_primary_10_1159_000365156 crossref_primary_10_1016_j_critrevonc_2016_01_021 crossref_primary_10_1016_j_ejca_2012_04_022 crossref_primary_10_1186_s12885_019_5335_8 crossref_primary_10_1007_s10549_015_3410_7 crossref_primary_10_1097_CCO_0b013e32833fb384 crossref_primary_10_1517_14712598_2014_873401 crossref_primary_10_1002_cncr_26579 crossref_primary_10_1158_1078_0432_CCR_14_1505 crossref_primary_10_1200_JCO_2014_56_7479 crossref_primary_10_1016_j_lungcan_2012_06_007 crossref_primary_10_1016_j_ctarc_2017_07_002 crossref_primary_10_1259_bjr_20140065 crossref_primary_10_1111_j_1549_8719_2011_00147_x crossref_primary_10_3390_cancers13010140 crossref_primary_10_4137_BCBCR_S7379 crossref_primary_10_4137_BCBCR_S32783 crossref_primary_10_3892_etm_2015_2586 crossref_primary_10_1684_bdc_2013_1740 crossref_primary_10_2147_JIR_S383191 crossref_primary_10_3816_CBC_2010_s_006 crossref_primary_10_1016_j_hoc_2012_02_013 crossref_primary_10_1038_bjc_2014_504 crossref_primary_10_1517_14712598_2014_939069 crossref_primary_10_1007_s10637_014_0093_6 crossref_primary_10_3390_ijms18010085 crossref_primary_10_1016_j_breast_2013_08_017 crossref_primary_10_1002_cam4_803 crossref_primary_10_1007_s10549_015_3599_5 crossref_primary_10_1158_1078_0432_CCR_15_1005 crossref_primary_10_3390_cancers14071852 crossref_primary_10_1186_1745_6215_14_228 crossref_primary_10_1007_s10549_012_2135_0 crossref_primary_10_1038_bjc_2016_427 crossref_primary_10_1016_j_critrevonc_2013_11_008 crossref_primary_10_4137_CMO_S34542 crossref_primary_10_1097_CAD_0b013e32833ed62e crossref_primary_10_1186_s40364_024_00714_6 crossref_primary_10_3390_ijms160511728 crossref_primary_10_1016_j_bulcan_2015_09_001 crossref_primary_10_1097_MD_0000000000003623 crossref_primary_10_1634_theoncologist_2009_0317 crossref_primary_10_1016_j_lfs_2024_122499 crossref_primary_10_1158_1078_0432_CCR_12_1652 crossref_primary_10_1080_14740338_2023_2248876 crossref_primary_10_1016_S1470_2045_15_70137_3 crossref_primary_10_1186_bcr3142 crossref_primary_10_1007_s10549_011_1785_7 crossref_primary_10_1155_2012_281261 crossref_primary_10_1016_S1470_2045_22_00506_X crossref_primary_10_1038_bjc_2017_116 crossref_primary_10_1634_theoncologist_2012_0339 crossref_primary_10_1007_s12282_016_0686_3 crossref_primary_10_1200_JCO_2010_34_1255 crossref_primary_10_1016_j_ejca_2012_08_005 crossref_primary_10_1007_s12609_011_0062_4 crossref_primary_10_5301_tj_5000555 crossref_primary_10_1158_1078_0432_CCR_12_3029 crossref_primary_10_1007_s00280_014_2505_x crossref_primary_10_1016_j_breast_2015_02_036 crossref_primary_10_1158_1078_0432_CCR_11_1001 crossref_primary_10_1016_j_ctrv_2017_09_001 crossref_primary_10_1016_S1548_5315_12_70003_7 crossref_primary_10_1093_jnci_djz211 crossref_primary_10_1684_bdc_2014_2014 crossref_primary_10_1007_s10549_013_2552_8 crossref_primary_10_1016_S1470_2045_10_70232_1 crossref_primary_10_1684_bdc_2014_2019 crossref_primary_10_1007_s11864_012_0181_9 crossref_primary_10_1517_13543784_2012_689824 crossref_primary_10_1517_14728214_2013_794784 crossref_primary_10_2217_imt_2016_0099 crossref_primary_10_3389_fonc_2022_1042451 crossref_primary_10_1093_annonc_mdr432 crossref_primary_10_1186_1756_0500_5_162 crossref_primary_10_1177_1060028019895783 crossref_primary_10_1080_0284186X_2022_2033832 crossref_primary_10_1200_JCO_2011_35_7376 crossref_primary_10_1016_j_ejca_2019_06_002 crossref_primary_10_1080_14779072_2019_1704626 crossref_primary_10_1186_s12929_016_0311_y crossref_primary_10_1038_s41571_019_0181_9 crossref_primary_10_1016_j_ctrv_2017_10_014 crossref_primary_10_3892_mmr_2013_1308 crossref_primary_10_1016_j_clbc_2013_11_005 crossref_primary_10_1016_S1470_2045_12_70566_1 crossref_primary_10_1136_jitc_2024_011314 crossref_primary_10_1016_j_ejso_2018_05_019 crossref_primary_10_1007_s10439_012_0655_8 crossref_primary_10_1007_s10549_013_2793_6 crossref_primary_10_1007_s13318_023_00855_3 crossref_primary_10_1002_cncr_26356 crossref_primary_10_1016_j_ejca_2020_02_022 crossref_primary_10_2217_fon_2016_0295 crossref_primary_10_1002_jcp_25685 crossref_primary_10_1007_s10549_013_2551_9 crossref_primary_10_1089_cbr_2010_0902 crossref_primary_10_1016_j_critrevonc_2015_02_007 crossref_primary_10_2217_fon_13_210 crossref_primary_10_1016_j_ctrv_2017_01_001 crossref_primary_10_1186_s12885_016_2823_y crossref_primary_10_3892_mco_2014_281 crossref_primary_10_1038_bjc_2012_304 crossref_primary_10_3390_ijms19010043 crossref_primary_10_1016_j_jval_2011_04_004 crossref_primary_10_1007_s10456_014_9424_7 crossref_primary_10_1007_s12094_018_02010_w crossref_primary_10_1080_14712598_2024_2408756 crossref_primary_10_1016_j_ejca_2016_09_024 crossref_primary_10_1111_ajco_12748 crossref_primary_10_1200_JCO_2014_58_1298 crossref_primary_10_1586_1744666X_2014_916211 crossref_primary_10_3390_ijms13089545 crossref_primary_10_1016_j_ccell_2014_10_006 crossref_primary_10_1016_j_breast_2014_08_015 crossref_primary_10_1159_000440958 crossref_primary_10_1517_14740338_2014_960388 crossref_primary_10_1097_PPO_0b013e318212db3c crossref_primary_10_1016_j_clon_2011_10_004 crossref_primary_10_4061_2011_572706 crossref_primary_10_1016_j_mehy_2011_06_035 crossref_primary_10_1016_j_canep_2012_01_004 crossref_primary_10_1007_s10549_023_07167_9 crossref_primary_10_18027_2224_5057_2018_8_3_68_77 crossref_primary_10_1007_s00595_014_0912_6 crossref_primary_10_1212_WNL_0000000000012642 crossref_primary_10_1080_14740338_2016_1182493 crossref_primary_10_1186_s12929_024_01011_y crossref_primary_10_3390_jcm8050612 crossref_primary_10_1016_j_ejca_2017_10_018 crossref_primary_10_1158_1078_0432_CCR_12_3585 crossref_primary_10_3389_fonc_2018_00227 crossref_primary_10_1007_s12032_010_9773_z crossref_primary_10_1634_theoncologist_2012_0043 crossref_primary_10_2165_11207720_000000000_00000 crossref_primary_10_1016_j_clbc_2020_04_009 crossref_primary_10_1016_j_nec_2012_05_002 crossref_primary_10_1155_2012_417673 crossref_primary_10_1038_clpt_2011_288 crossref_primary_10_1177_1758834010397627 crossref_primary_10_1016_j_ctrv_2012_01_001 crossref_primary_10_1371_journal_pone_0136324 crossref_primary_10_1002_jbt_23348 crossref_primary_10_1007_s10549_011_1695_8 crossref_primary_10_1016_j_critrevonc_2020_102988 crossref_primary_10_1177_1758834012444711 crossref_primary_10_3892_ol_2015_3348 crossref_primary_10_1038_nrclinonc_2011_66 crossref_primary_10_1097_CAD_0000000000001192 crossref_primary_10_1016_j_critrevonc_2015_01_012 crossref_primary_10_1016_j_jnci_2014_10_002 crossref_primary_10_1016_j_lungcan_2013_01_015 crossref_primary_10_1177_1010428317711033 crossref_primary_10_1097_GCO_0b013e32835c1633 crossref_primary_10_1007_s00520_013_1821_8 crossref_primary_10_1016_j_clbc_2013_12_003 crossref_primary_10_1200_JCO_2014_58_3690 crossref_primary_10_1007_s00228_014_1687_9 crossref_primary_10_1016_j_breast_2019_02_002 crossref_primary_10_1016_j_procbio_2018_03_004 crossref_primary_10_1155_2013_379641 crossref_primary_10_1177_039463201302600323 crossref_primary_10_3389_fonc_2021_628138 crossref_primary_10_1158_1078_0432_CCR_10_1962 crossref_primary_10_1002_ijc_32163 crossref_primary_10_1208_s12248_022_00755_5 crossref_primary_10_1634_theoncologist_2014_0002 crossref_primary_10_3390_cancers6042187 crossref_primary_10_1002_jrsm_1259 crossref_primary_10_1186_bcr2907 crossref_primary_10_1016_j_clbc_2013_02_008 crossref_primary_10_1093_annonc_mdr344 crossref_primary_10_1016_j_clbc_2016_02_003 crossref_primary_10_1371_journal_pone_0061788 crossref_primary_10_1016_S1470_2045_14_70480_2 crossref_primary_10_1016_j_semcancer_2022_02_009 crossref_primary_10_1093_jncimonographs_lgr027 crossref_primary_10_1007_s11060_023_04276_9 crossref_primary_10_1186_1471_2407_14_820 crossref_primary_10_1016_j_canlet_2014_10_028 crossref_primary_10_1007_s12032_013_0776_4 crossref_primary_10_1038_tpj_2016_25 crossref_primary_10_1038_nrclinonc_2012_64 crossref_primary_10_1002_cncr_32832 crossref_primary_10_1016_j_phrs_2018_03_021 crossref_primary_10_1007_s10237_022_01587_0 crossref_primary_10_1016_S1470_2045_14_70439_5 crossref_primary_10_3389_fcvm_2023_1078135 crossref_primary_10_1634_theoncologist_2011_0198 crossref_primary_10_1056_NEJMoa1505067 crossref_primary_10_1093_annonc_mdq122 crossref_primary_10_1188_13_CJON_S1_15_21 crossref_primary_10_3390_cancers15061776 crossref_primary_10_3390_cancers13174399 crossref_primary_10_1200_JCO_2012_46_2762 crossref_primary_10_1016_j_ejca_2024_115072 crossref_primary_10_1245_s10434_016_5662_9 crossref_primary_10_1186_s12885_023_10768_8 crossref_primary_10_1002_cncr_29893 crossref_primary_10_1016_j_breast_2012_03_003 crossref_primary_10_1200_JCO_2012_44_7912 crossref_primary_10_1007_s00280_010_1475_x crossref_primary_10_1586_era_11_80 crossref_primary_10_2174_0929867325666180209124052 crossref_primary_10_1158_1078_0432_CCR_10_1868 crossref_primary_10_1111_tbj_13369 crossref_primary_10_2217_pme_14_30 crossref_primary_10_1016_j_clbc_2016_07_005 crossref_primary_10_1586_era_13_20 crossref_primary_10_2217_bmt_12_57 crossref_primary_10_1016_j_clbc_2012_07_004 crossref_primary_10_3389_fendo_2024_1465727 crossref_primary_10_1007_s11523_020_00730_0 crossref_primary_10_4103_jcrt_jcrt_1879_20 crossref_primary_10_1080_1120009X_2021_1947022 crossref_primary_10_1016_S1470_2045_15_00041_8 crossref_primary_10_7759_cureus_19471 crossref_primary_10_1097_01_cco_0000397417_75245_9c crossref_primary_10_1007_s10456_014_9438_1 crossref_primary_10_1038_srep36694 crossref_primary_10_1016_j_clbc_2017_05_006 crossref_primary_10_2217_bmt_12_62 crossref_primary_10_4161_2162402X_2014_985940 crossref_primary_10_1097_CCO_0b013e32834bf8ae crossref_primary_10_1007_s40265_013_0154_8 crossref_primary_10_1016_j_clbc_2013_09_009 crossref_primary_10_1016_j_jddst_2023_104673 crossref_primary_10_1088_2057_1739_1_1_015002 crossref_primary_10_1186_2193_1801_2_202 crossref_primary_10_2217_bmt_13_37 crossref_primary_10_1200_JCO_2011_38_8942 crossref_primary_10_1371_journal_pone_0133133 crossref_primary_10_2217_fon_14_206 crossref_primary_10_1097_COC_0b013e31827e4e9a crossref_primary_10_1002_jmri_24079 crossref_primary_10_1097_SAP_0b013e31824e5e57 crossref_primary_10_1007_s10549_012_2285_0 crossref_primary_10_1016_j_breast_2022_07_014 crossref_primary_10_1016_j_ctrv_2014_02_001 crossref_primary_10_1159_000504527 crossref_primary_10_3390_ijms131114845 crossref_primary_10_1016_j_critrevonc_2012_09_009 crossref_primary_10_1056_NEJMoa1111065 crossref_primary_10_3389_fmed_2025_1513836 crossref_primary_10_1007_s12094_015_1476_7 crossref_primary_10_1200_JCO_2010_33_2684 crossref_primary_10_1007_s11060_011_0607_4 crossref_primary_10_1038_nrclinonc_2011_21 crossref_primary_10_2217_fon_2015_0065 crossref_primary_10_1002_ijc_28829 crossref_primary_10_1016_j_ctrv_2011_12_002 crossref_primary_10_1016_j_ctrv_2017_07_006 crossref_primary_10_1016_j_ejca_2012_06_014 crossref_primary_10_2217_cer_13_50 crossref_primary_10_1007_s12282_012_0344_3 crossref_primary_10_1200_JCO_2011_38_2010 crossref_primary_10_2217_fon_12_22 crossref_primary_10_1002_psp4_12629 crossref_primary_10_1016_S0959_8049_11_70145_9 crossref_primary_10_1155_2011_696208 crossref_primary_10_1093_jnci_djr238 crossref_primary_10_1007_s10549_014_3217_y crossref_primary_10_3390_pharmaceutics12060524 crossref_primary_10_1007_s10637_014_0122_5 crossref_primary_10_1007_s12254_017_0362_0 crossref_primary_10_1007_s10549_012_2060_2 crossref_primary_10_1007_s00761_013_2450_z crossref_primary_10_1634_theoncologist_2016_0067 crossref_primary_10_1016_j_pcad_2010_05_006 crossref_primary_10_1586_14737140_2014_846220 crossref_primary_10_1007_s00761_012_2360_5 crossref_primary_10_1016_j_biopha_2018_12_117 crossref_primary_10_1007_s00280_014_2628_0 crossref_primary_10_1186_s12967_018_1443_5 crossref_primary_10_1016_S1470_2045_14_70475_9 crossref_primary_10_1016_j_tranon_2016_07_002 crossref_primary_10_1371_journal_pone_0131095 crossref_primary_10_1073_pnas_1215397109 crossref_primary_10_1158_1078_0432_CCR_13_0572 crossref_primary_10_3390_ijms151223024 crossref_primary_10_1007_s11864_011_0168_y crossref_primary_10_1517_17460441_2012_695774 crossref_primary_10_1136_jitc_2020_000696 crossref_primary_10_1016_j_lfs_2024_122615 crossref_primary_10_3390_cancers14051302 crossref_primary_10_1016_j_clbc_2024_01_018 crossref_primary_10_3389_fonc_2019_01455 crossref_primary_10_1007_s00129_012_3091_9 crossref_primary_10_1007_s10549_012_2008_6 crossref_primary_10_1002_cam4_7181 crossref_primary_10_1586_era_12_13 crossref_primary_10_1016_S1470_2045_12_70049_9 crossref_primary_10_1038_s41419_024_07223_2 crossref_primary_10_3892_or_2017_5668 crossref_primary_10_1038_s41591_018_0009_7 crossref_primary_10_1097_CAD_0b013e32834e735a crossref_primary_10_1097_SPC_0000000000000022 crossref_primary_10_1371_journal_pone_0051780 crossref_primary_10_1159_000539717 crossref_primary_10_1371_journal_pone_0072021 crossref_primary_10_1517_14712598_2011_594436 crossref_primary_10_1684_bdc_2012_1586 crossref_primary_10_1016_j_critrevonc_2017_08_010 crossref_primary_10_1093_annonc_mdq430 crossref_primary_10_3892_ijo_2013_1938 crossref_primary_10_1097_SLA_0000000000006084 crossref_primary_10_1007_s13691_015_0222_x crossref_primary_10_1016_j_ajog_2020_09_045 crossref_primary_10_3390_toxics3020152 crossref_primary_10_1002_phar_2344 crossref_primary_10_1007_s10330_011_0812_9 crossref_primary_10_1016_j_canlet_2021_08_005 crossref_primary_10_1016_S1470_2045_23_00357_1 crossref_primary_10_1016_j_steroids_2011_02_036 crossref_primary_10_1007_s10555_013_9451_7 crossref_primary_10_1096_fj_202002414R crossref_primary_10_1007_s00432_014_1590_x crossref_primary_10_1007_s11912_012_0238_8 crossref_primary_10_1016_j_ctrv_2014_01_003 crossref_primary_10_1016_j_breast_2014_04_002 crossref_primary_10_1186_bcr2642 crossref_primary_10_1016_j_ctrv_2017_06_007 crossref_primary_10_4155_fmc_11_38 crossref_primary_10_1038_srep28888 crossref_primary_10_1093_annonc_mdq543 crossref_primary_10_1007_s12094_015_1334_7 crossref_primary_10_1016_S1470_2045_13_70012_3 crossref_primary_10_1007_s00280_011_1604_1 crossref_primary_10_1007_s12609_012_0094_4 crossref_primary_10_1186_s42269_022_00854_5 crossref_primary_10_1038_nm_4197 crossref_primary_10_1007_s00508_023_02254_9 crossref_primary_10_1111_j_1524_4741_2012_01246_x crossref_primary_10_1016_j_clbc_2013_08_003 crossref_primary_10_1016_j_ejphar_2023_175586 crossref_primary_10_1038_nrd_2015_17 crossref_primary_10_1158_1078_0432_CCR_12_3177 crossref_primary_10_3389_fphar_2023_1108772 crossref_primary_10_1016_j_ctrv_2011_11_005 crossref_primary_10_1186_1471_2407_12_482 crossref_primary_10_1002_cncr_30141 crossref_primary_10_1155_2012_385978 crossref_primary_10_1016_j_canlet_2013_05_015 crossref_primary_10_1007_s10549_012_1957_0 crossref_primary_10_2147_BCTT_S274514 crossref_primary_10_1007_s10269_011_2083_z crossref_primary_10_1093_annonc_mdx065 crossref_primary_10_1002_med_21496 crossref_primary_10_1007_s00280_014_2607_5 crossref_primary_10_1016_j_bbcan_2022_188789 crossref_primary_10_1038_s41523_022_00462_6 crossref_primary_10_1186_1748_717X_6_48 crossref_primary_10_1016_j_ejca_2011_12_007 crossref_primary_10_1016_j_ejca_2016_11_002 crossref_primary_10_1016_j_jfma_2015_03_005 crossref_primary_10_1146_annurev_med_051413_024741 crossref_primary_10_1016_j_ejca_2011_06_018 crossref_primary_10_1186_s40064_016_1736_1 crossref_primary_10_2217_pgs_14_140 crossref_primary_10_1016_j_ygyno_2013_04_049 crossref_primary_10_1007_s12282_020_01052_9 crossref_primary_10_1016_j_breast_2013_03_012 crossref_primary_10_1056_NEJMoa1111097 crossref_primary_10_1634_theoncologist_2016_0265 crossref_primary_10_2217_pgs_13_101 crossref_primary_10_1016_j_jddst_2020_101989 crossref_primary_10_1096_fj_202002533R crossref_primary_10_14694_EdBook_AM_2012_32_306 crossref_primary_10_1007_s12094_011_0737_3 crossref_primary_10_1053_j_seminoncol_2017_10_010 crossref_primary_10_1080_14737140_2016_1247698 crossref_primary_10_1016_j_ctrv_2013_09_015 crossref_primary_10_1634_theoncologist_2011_0115 crossref_primary_10_1016_j_intimp_2023_110214 crossref_primary_10_1684_bdc_2012_1676 crossref_primary_10_1634_theoncologist_2011_0113 crossref_primary_10_1002_sim_10129 crossref_primary_10_1016_j_critrevonc_2011_12_004 crossref_primary_10_1016_j_breast_2012_01_012 crossref_primary_10_1002_phar_1147 crossref_primary_10_1186_1756_0500_6_254 crossref_primary_10_1371_journal_pone_0145442 crossref_primary_10_1007_s10549_016_3727_x crossref_primary_10_1111_j_1743_7563_2012_01569_x crossref_primary_10_1093_annonc_mdw077 crossref_primary_10_1158_1078_0432_CCR_13_1865 crossref_primary_10_1002_cncr_33992 crossref_primary_10_1001_jama_2011_51 crossref_primary_10_1007_s40261_014_0222_1 crossref_primary_10_1172_JCI70212 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1200/JCO.2008.21.6457 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1527-7755 |
| ExternalDocumentID | 20498403 |
| Genre | Clinical Trial, Phase III Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .55 0R~ 18M 2WC 34G 39C 3O- 4.4 53G 5GY 5RE 8F7 AARDX AAWTL AAYEP AAYOK ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AFFNX AI. AIAGR ALMA_UNASSIGNED_HOLDINGS AWKKM BAWUL C45 CGR CS3 CUY CVF DIK EBS ECM EIF EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 KQ8 L7B LSO MJL N4W N9A NPM O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN SV3 TEORI TR2 TWZ UDS VH1 VVN WH7 X7M YCJ YFH YQY 7X8 ABBLC |
| ID | FETCH-LOGICAL-c397t-254d474570dfdf5ea715d0dd6bc36cd48ad19f13ac6cb4a1db5597dff2a081242 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 768 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000279637600008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1527-7755 |
| IngestDate | Fri Sep 05 09:09:44 EDT 2025 Thu Jan 02 22:05:06 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 20 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c397t-254d474570dfdf5ea715d0dd6bc36cd48ad19f13ac6cb4a1db5597dff2a081242 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 20498403 |
| PQID | 733654784 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_733654784 pubmed_primary_20498403 |
| PublicationCentury | 2000 |
| PublicationDate | 2010-07-10 |
| PublicationDateYYYYMMDD | 2010-07-10 |
| PublicationDate_xml | – month: 07 year: 2010 text: 2010-07-10 day: 10 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of clinical oncology |
| PublicationTitleAlternate | J Clin Oncol |
| PublicationYear | 2010 |
| SSID | ssj0014835 |
| Score | 2.5567884 |
| Snippet | The efficacy and safety of combining bevacizumab (7.5 and 15 mg/kg) with docetaxel as first-line therapy for human epidermal growth factor receptor 2 (HER2)... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 3239 |
| SubjectTerms | Adult Aged Aged, 80 and over Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - pathology Drug Administration Schedule Female Humans Middle Aged Neoplasm Metastasis Neoplasm Recurrence, Local - drug therapy Placebos - administration & dosage Receptor, Epidermal Growth Factor - metabolism Taxoids - administration & dosage |
| Title | Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/20498403 https://www.proquest.com/docview/733654784 |
| Volume | 28 |
| WOSCitedRecordID | wos000279637600008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9tAEF2VUiEupeUbWjSHKicWbGf9wQmhCNRUkOYQpNyi_USRgh3iBEr_G_-NmbWTSEgVh14sW7JXK-14983O2_cY-xG4iFYtzbWUgoss0JxgOQ-MiDE8lFDSi7hep51O1u-fdWtuTlnTKudzop-oTaFpj_yUZPtIe0qcjx84mUZRcbV20Fhhq01EMsToSvvLIoLIvL8mGbciiIzjukqJcXH6q_W74lFG4Uki4vTf-NKvM1cb_9nDL-xzDTDhooqIr-yDzTfZ2k1dQt9kjW4lVv18DL3l2avyGBrQXcpYP2-xF3wsLbTbbfAatFA4UPZR6uHf2b1UMB7NSsBe2an8Y0cwJ7MD7eyCp3qp4u1LiJABESe4IYJOTggXFkx3at87BoIl11rsyQjuJsUTtlaZAgFOznZMNxHP7Z1XLId7bJkORQ01KOLXT0FTHE-22e3VZa_1k9dmD1wjJJpyTFSNSHEoAuOMi61Mw9gExiRKNxNtRCZNeObCptSJVkKGRlEuZJyLZEAgJdphH_Mit3sMCIM6i7m3zEJhjJY2MUki01glwgTa7jOYD-AAfyaqkMjcFrNysBjCfbZbBcFgXIl-DCJMpTAZbh68__EhW684Bikuct_YqsOJxH5nn_TjdFhOjnyQ4rXTvXkF6wv2wg |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Phase+III+study+of+bevacizumab+plus+docetaxel+compared+with+placebo+plus+docetaxel+for+the+first-line+treatment+of+human+epidermal+growth+factor+receptor+2-negative+metastatic+breast+cancer&rft.jtitle=Journal+of+clinical+oncology&rft.au=Miles%2C+David+W&rft.au=Chan%2C+Arlene&rft.au=Dirix%2C+Luc+Y&rft.au=Cort%C3%A9s%2C+Javier&rft.date=2010-07-10&rft.issn=1527-7755&rft.eissn=1527-7755&rft.volume=28&rft.issue=20&rft.spage=3239&rft_id=info:doi/10.1200%2FJCO.2008.21.6457&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-7755&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-7755&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-7755&client=summon |